The establishment of rules that link sequence and amyloid feature is critical for our understanding of misfolding diseases. To this end, we have performed a saturation mutagenesis analysis on the de novodesigned amyloid peptide STVIIE (1). The positional scanning mutagenesis has revealed that there is a position dependence on mutation of amyloid fibril formation and that both very tolerant and restrictive positions to mutation can be found within an amyloid sequence. In this system, mutations that accelerate -sheet polymerization do not always lead to an increase of amyloid products. On the contrary, abundant fibrils are typically found for mutants that polymerize slowly. From these experiments, we have extracted a sequence pattern to identify amyloidogenic stretches in proteins. The pattern has been validated experimentally. In silico sequence scanning of amyloid proteins also supports the pattern. Analysis of protein databases has shown that highly amyloidogenic sequences matching the pattern are less frequent in proteins than innocuous amino acid combinations and that, if present, they are surrounded by amino acids that disrupt their aggregating capability (amyloid breakers). This study provides the potential for a proteome-wide scanning to detect fibril-forming regions in proteins, from which molecules can be designed to prevent and͞or disrupt this process.I t is accepted that misfolding of peptides and proteins cause the fibrillar aggregates that characterize the group of diseases known as amyloidoses (1, 2). Despite active research, a detailed understanding of the molecular principles underlying the transformation of soluble proteins into amyloid aggregates is still lacking (1-3).The group of peptides and proteins capable of forming amyloid fibrils is very diverse (4-8). This group does not only consist of proteins involved in amyloid deposits in vivo (4), but also of nonpathogenic (15, 16) and designed peptides and proteins (7,8). X-ray fiber diffraction data indicate that all amyloid fibrils share a cross--structure, regardless of the sequence or native fold of the soluble precursor (1, 2). Thus, an increasingly adopted view is that the ability to form amyloid fibrils is a general property of the polypeptide backbone (6). Nevertheless, the propensity of a given polypeptide to form amyloid fibrils depends enormously on amino acid composition (7-10).A protein has to be partially or fully unfolded to aggregate (1, 2). Yet, mutations leading to aggregation can alter (9, 10), or not alter (11, 12), protein stability. Aggregation from some peptides and proteins involved in relevant amyloidoses, such as type II diabetes and Alzheimer's and Parkinson's disease, does not require, however, previous unfolding, because these molecules are largely unstructured under physiological conditions (2). Nevertheless, most of the natively unfolded proteins in vivo do not undergo aggregation (13), indicating that unfolding is necessary, but not sufficient, to promote aggregation. Hence, there must be some sequence motifs tha...